Elicio Therapeutics, Inc. Stock Analysis & AI Score
Elicio Therapeutics, Inc. (ELTX) has an ST Score of 27.5 (D+), driven by its Forecast (B+) and held back by its Momentum (F). Analysts rate it Buy with a $11.83 price target (+529.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Elicio Therapeutics, Inc. (ELTX) has an ST Score of 27.5 (D+), driven by its Forecast (B+) and held back by its Momentum (F). Analysts rate it Buy with a $11.83 price target (+529.3% upside).
- Strongest
- ForecastB+
- Weakest
- MomentumF
All factor grades
- ForecastB+
- GrowthC+
- ValuationC
- Financial StrengthD
- ProfitabilityF
- MomentumF
- Piotroski2/9
Contact
ELTX stock: frequently asked questions
What is ELTX's ST Score?
Elicio Therapeutics, Inc. (ELTX) has an ST Score of 27.5 (D+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ELTX a buy, hold, or sell?
Analysts rate ELTX a Buy, with a price target of $11.83 (+529.3% vs the current price). Our ST Score grades it D+ (27.5/100). The ST Score is a data-driven signal, not a recommendation.
What are ELTX's factor grades?
Valuation C, Profitability F, Financial Strength D, Momentum F, Growth C+, Forecast B+.
What is ELTX's valuation grade?
Elicio Therapeutics, Inc. (ELTX) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ELTX's growth grade?
Elicio Therapeutics, Inc. (ELTX) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ELTX's profitability grade?
Elicio Therapeutics, Inc. (ELTX) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ELTX's financial strength grade?
Elicio Therapeutics, Inc. (ELTX) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ELTX?
The average analyst price target for Elicio Therapeutics, Inc. (ELTX) is $11.83 from 4 analysts, which is +529.3% versus the recent price of $1.88.
What is ELTX's Piotroski score?
Elicio Therapeutics, Inc. (ELTX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.